BioStock: Cyxone about the advancements in the T20K project

Biotech company Cyxone recently announced the next step in the T20K project, their drug candidate for multiple sclerosis. The company has signed an agreement with a renowned European contract development and manufacturing organisation for the scale up and manufacturing of the active ingredient of T20K. BioStock reached out to Cyxone’s CEO Tara Heitner for a comment.

Read the interview with Cyxone's CEO Tara Heitner at biostock.se:

https://www.biostock.se/en/2022/02/cyxone-on-the-advancements-in-the-t20k-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/